GGrantIndex
← Leaderboards

Alex Toker

Beth Israel Deaconess Medical Center

Google Scholar ↗PubMed ↗ORCID ↗
$16,651,718
Attributed
$17,756,740
Total exposure
10
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.2M · FY2005–25
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$17,756,740 · 10

By mechanism

R01$11,364,841 · 5
R35$5,837,252 · 1
R21$546,795 · 2
R13$7,852 · 2

Top collaborators

Most similar at Beth Israel Deaconess Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Signal Transduction”

Research focus

Signal TransductionPhenotypeMalignant NeoplasmsMediatingPathway InteractionsRegulationPhosphatidylinositolsResponseInsightTumor ProgressionPhosphotransferasesTranscription FactorBaseBreast Cancer CellTumorigenesisCell SurvivalPhosphorylationPlayOncogenicNovel TherapeuticsSignal PathwayMammary NeoplasmsIn VitroCancer Cell

Grant awards (47)

Discovery, Regulation and Function of the PI 3-Kinase and AKT Pathway in Cancer$1,050,000
R35 · FY2025 · CA · contact PI
Discovery, Regulation and Function of the PI 3-Kinase and AKT Pathway in Cancer$997,501
R35 · FY2024 · CA · contact PI
Discovery, Regulation and Function of the PI 3-Kinase and AKT Pathway in Cancer$975,131
R35 · FY2023 · CA · contact PI
Discovery, Regulation and Function of the PI 3-Kinase and AKT Pathway in Cancer$1,008,445
R35 · FY2022 · CA · contact PI
FASEB Science Research Conference: Protein Kinases and Protein Phosphorylation$3,500
R13 · FY2022 · CA · contact PI
Discovery, Regulation and Function of the PI 3-Kinase and AKT Pathway in Cancer$1,035,000
R35 · FY2021 · CA · contact PI
Discovery, Regulation and Function of the PI 3-Kinase and AKT Pathway in Cancer$771,175
R35 · FY2020 · CA · contact PI
Exploiting Metabolic Vulnerabilities in the PI3K and Akt Pathway in Cancer for Therapeutic Benefit$395,738
R01 · FY2020 · CA · contact PI
Novel regulation of PI3K/Akt to direct targeted breast cancer therapies$415,625
R01 · FY2019 · CA · contact PI
Exploiting Metabolic Vulnerabilities in the PI3K and Akt Pathway in Cancer for Therapeutic Benefit$383,865
R01 · FY2019 · CA · contact PI
Exploiting Metabolic Vulnerabilities in the PI3K and Akt Pathway in Cancer for Therapeutic Benefit$395,738
R01 · FY2018 · CA · contact PI
Exploiting Metabolic Vulnerabilities in the PI3K and Akt Pathway in Cancer for Therapeutic Benefit$395,738
R01 · FY2017 · CA · contact PI
Novel regulation of PI3K/Akt to direct targeted breast cancer therapies$361,050
R01 · FY2017 · CA · contact PI
Exploiting Metabolic Vulnerabilities in the PI3K and Akt Pathway in Cancer for Therapeutic Benefit$395,738
R01 · FY2016 · CA · contact PI
Novel regulation of PI3K/Akt to direct targeted breast cancer therapies$361,050
R01 · FY2016 · CA · contact PI
Novel regulation of PI3K/Akt to direct targeted breast cancer therapies$361,050
R01 · FY2015 · CA · contact PI
Identifying lincRNAs that Mediate PI 3 Kinase Dependent Breast Cancer$227,070
R21 · FY2015 · CA · contact PI
Novel regulation of PI3K/Akt to direct targeted breast cancer therapies$350,219
R01 · FY2014 · CA · contact PI
Identifying lincRNAs that Mediate PI 3 Kinase Dependent Breast Cancer$189,225
R21 · FY2014 · CA · contact PI
Novel regulation of PI3K/Akt to direct targeted breast cancer therapies$361,050
R01 · FY2013 · CA · contact PI
Role of NFAT and NFAT-Induced Genes in Carcinoma$277,510
R01 · FY2013 · CA · contact PI
Role of NFAT and NFAT-Induced Genes in Carcinoma$295,224
R01 · FY2012 · CA · contact PI
Role of NFAT and NFAT-Induced Genes in Carcinoma$295,224
R01 · FY2011 · CA · contact PI
The Akt and NFAT Pathway and the Regulaton of Cancer Cell Motility$281,979
R01 · FY2011 · CA · contact PI
Role of NFAT and NFAT-Induced Genes in Carcinoma$304,354
R01 · FY2010 · CA · contact PI
The Akt and NFAT Pathway and the Regulaton of Cancer Cell Motility$290,700
R01 · FY2010 · CA · contact PI
Role of NFAT and NFAT-Induced Genes in Carcinoma$304,354
R01 · FY2009 · CA · contact PI
The Akt and NFAT Pathway and the Regulaton of Cancer Cell Motility$290,700
R01 · FY2009 · CA · contact PI
The Akt and NFAT Pathway and the Regulaton of Cancer Cell Motility$290,700
R01 · FY2008 · CA · contact PI
Regulation and function of the PKC/PKD signaling pathway$290,144
R01 · FY2008 · CA · contact PI
The Akt and NFAT Pathway and the Regulaton of Cancer Cell Motility$290,700
R01 · FY2007 · CA · contact PI
Regulation and function of the PKC/PKD signaling pathway$290,144
R01 · FY2007 · CA · contact PI
FASEB Summer Research Conference on Lipid Signaling Pathways in Cancer$4,352
R13 · FY2007 · CA · contact PI
Regulation and function of the PKC/PKD signaling pathway$298,809
R01 · FY2006 · CA · contact PI
Role of PLCgamma and NFAT Signaling Pathway in Carcinoma$295,489
R01 · FY2006 · CA · contact PI
Regulation and function of the PKC/PKD signaling pathway$306,000
R01 · FY2005 · CA
Role of PLCgamma and NFAT Signaling Pathway in Carcinoma$302,600
R01 · FY2005 · CA
Regulation and function of the PKC/PKD signaling pathway$306,000
R01 · FY2004 · CA
Role of PLCgamma and NFAT Signaling Pathway in Carcinoma$302,600
R01 · FY2004 · CA
PHOSPHOINOSITIDE 3-KINASE C SIGNALING$32,676
R01 · FY2004 · CA
Role of PLCgamma and NFAT Signaling Pathway in Carcinoma$302,600
R01 · FY2003 · CA
PHOSPHOINOSITIDE 3-KINASE C SIGNALING$287,712
R01 · FY2003 · CA
PHOSPHOINOSITIDE 3-KINASE C SIGNALING$316,252
R01 · FY2002 · CA
Role of PLCgamma and NFAT Signaling Pathway in Carcinoma$302,600
R01 · FY2002 · CA
PHOSPHOINOSITIDE 3-KINASE C SIGNALING$341,840
R01 · FY2001 · CA
PHOSPHOINOSITIDE 3-KINASE C SIGNALING$291,069
R01 · FY2000 · CA
PHOSPHOLIPASE C SIGNALING IN INTEGRIN MEDIATED CARCINOMA$130,500
R21 · FY2000 · CA